Onconova Therapeutics, Inc.·4

Feb 9, 5:38 PM ET

Guerin Mark Patrick 4

4 · Onconova Therapeutics, Inc. · Filed Feb 9, 2024

Insider Transaction Report

Form 4
Period: 2024-02-07
Guerin Mark Patrick
Chief Accounting Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2024-02-076,9006,900 total
    Common Stock (6,900 underlying)
  • Exercise/Conversion

    Common Stock

    2024-02-07+6,90032,344 total
  • Tax Payment

    Common Stock

    2024-02-07$0.67/sh2,443$1,63729,901 total
Footnotes (2)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

Documents

1 file
  • 4
    form4-02092024_100205.xmlPrimary